SIBIONICS
Innovating for You: Revolutionizing Diabetes Care with Every Step.
Since our founding in 2015, SIBIONICS has been at the forefront of transforming diabetes management. Born from a commitment to innovation and a profound understanding of the everyday challenges faced by those with diabetes, we've consistently aimed to redefine the landscape of Continuous Glucose Monitoring (CGM) systems. By merging cutting-edge technology with designs centered around the user, we deliver solutions that not only meet needs but exceed expectations.
Today, with over 1,000,000 users across the globe, SIBIONICS stands as a beacon of reliability and innovation in diabetes care. Our global presence is a testament to the effectiveness of our CGM solutions and our dedication to making a significant, positive impact worldwide.
Looking ahead, SIBIONICS is committed to continuing our legacy of innovation. We're not just keeping pace; we're setting the pace—constantly pushing the boundaries of what's possible in CGM technology and striving for excellence with each new product we introduce.
Innover underliggende teknologier for å tjene folkehelsen
Vi fokuserer på helseledelsesbehovene til den mest omfattende befolkningen, og bryr oss også om sykdomsdiagnostikk og terapeutiske regimer for populasjoner med sjeldne sykdommer. Vi har integrert et utmerket forskerteam for å kontinuerlig transformere banebrytende vitenskapelige forskningsresultater til medisinske produkter, og tjene folkehelsen.
Teknologisk innsikt i det ukjente vekker potensiale for liv
Basert på pasientbehov introduserer vi biokjemi, brikkedesign, kunstig intelligens, automatisering og andre teknologier for å få innsikt i de ukjente områdene av helsedata og hjelpe mennesker med å gjøre endringer mot bedre livskvalitet
Sertifikater
Vi er dedikerte til å hjelpe kunder med å forbedre produktkvaliteten og møte utfordringer.
Milepæler og produktutvalg
2023
The GS1 CGM system received the CE mark for entering the European market.
2021
The continuous glucose monitoring system (CGM) was submitted to National Medical Products Administration for registration and was approved. The practicing license of Yinchuan Sibionics Internet Hospital was approved.
2020
AI-DR was approved as the first Class III medical device for AI-assisted fundus disease diagnosis software in China. Sibionics was certified as National High-tech Enterprise.
2019
Fundus camera obtained the registration certificate for Class II medical device. R&D of capsule endoscopy project was started.
2016
R&D of continuous glucose monitoring system (CGM) was started. R&D of diabetic retinopathy AI-assisted diagnosis software (AI-DR) was started.
2015
Sibionics was established, and American R&D Center was established. R&D of artificial retina project was started.
